MTLS — Materialise N.V.

Summary of Materialise (MTLS) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Revenue: EUR 70.2 million, up 6.8% year-on-year.
• Gross Profit: EUR 40.8 million, representing a gross margin of 58.1%.
• Adjusted EBIT: EUR 4 million (5.7% margin), a significant improvement from a loss of EUR 1.2 million in Q4 2024.
• Net Profit: EUR 6.2 million (EUR 0.11 per share), more than double the EUR 2.9 million from the previous year.
• Full Year Revenue: EUR 268 million, flat compared to 2024.
• Net Cash Position: Improved to EUR 70.8 million, with cash reserves at EUR 134 million.

2. Strategic Updates and Business Highlights

• Dual Listing: Completed a dual listing on Euronext Brussels, enhancing investor access and operational flexibility.
• Share Buyback Program: Announced a buyback program of up to EUR 30 million, with initial purchases already made.
• Medical Segment Growth: Surpassed 700,000 patients treated with personalized solutions; Q4 revenue grew by over 16%.
• Software Innovations: Launched new CO-AM solutions and a new version of Mimics Flow, enhancing automation and interoperability.
• Manufacturing Strategy: Merged iMaterialise and Materialise Onsite into a single platform to focus on professional 3D printing.

3. Forward Guidance and Outlook

• 2026 Revenue Forecast: Expected to be between EUR 273 million and EUR 283 million.
• Segment Growth: Anticipates continued double-digit growth in the Medical segment, while the Software segment will complete its transition to a cloud-based model.
• Manufacturing Challenges: Expects ongoing macroeconomic headwinds, particularly in the prototyping sector, impacting growth.

4. Bad News, Challenges, or Points of Concern

• Manufacturing Decline: Revenue in the Manufacturing segment fell 2% in Q4, with a 13% decline for the full year.
• Macroeconomic Headwinds: Persistent challenges in the industrial market, particularly in Europe, are expected to continue affecting the Manufacturing segment.
• Prototyping Demand: A significant portion of Manufacturing revenue is tied to prototyping, which has been declining, posing risks to profitability in this segment.

5. Notable Q&A Insights

• Manufacturing Outlook: Management confirmed expectations for Manufacturing to remain flat or decline in 2026 due to ongoing industrial challenges.
• Cost Management: Discussion on potential cost optimizations in the Manufacturing segment, with a focus on improving margins through strategic sector investments.
• Operational Expenses: Q4 operating expenses were impacted by nonrecurring costs related to the Euronext listing, suggesting that future projections should account for this anomaly.

Overall, while Materialise demonstrated solid growth in its Medical segment and improved profitability metrics, challenges in the Manufacturing sector and macroeconomic conditions present ongoing risks that management is actively addressing.